Quest Diagnostics Q1 2024 Adj EPS $2.04 Beats $1.86 Estimate, Sales $2.366B Beat $2.287B Estimate
Portfolio Pulse from Benzinga Newsdesk
Quest Diagnostics reported Q1 2024 adjusted EPS of $2.04, surpassing the $1.86 estimate, and sales of $2.366B, exceeding the $2.287B estimate. This represents a year-over-year sales increase of 1.50%.
April 23, 2024 | 10:46 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Quest Diagnostics exceeded Q1 2024 earnings and sales estimates, with an EPS of $2.04 and sales of $2.366B.
Beating both earnings and sales estimates typically leads to positive investor sentiment and can result in a short-term stock price increase. The reported growth in sales compared to the same period last year further strengthens the positive outlook for DGX.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100